Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients Who Have Completed Protocol TB006AD2102 and in De Novo Patients With Alzheimer's Disease

Next Previous
Search
Trial Profile

A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients Who Have Completed Protocol TB006AD2102 and in De Novo Patients With Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TB 006 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors TrueBinding

    • Most Recent Events

    • 10 Dec 2024 Status changed from active, no longer recruiting to discontinued due to resource constraints
    • 28 Mar 2023 Early results from an Open-Label Extension (OLE) study published in the Truebinding Media Release
    • 14 Mar 2023 According to Truebinding media release, company has been granted a Type-B End-of-Phase 2 (EOP2) meeting with the USFDA which will take place in April 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top